Cargando…
Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease
Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot stud...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356654/ https://www.ncbi.nlm.nih.gov/pubmed/30597973 http://dx.doi.org/10.3390/cells8010014 |
_version_ | 1783391601250271232 |
---|---|
author | Ueno, Shin-Ichi Saiki, Shinji Fujimaki, Motoki Takeshige-Amano, Haruka Hatano, Taku Oyama, Genko Ishikawa, Kei-Ichi Yamaguchi, Akihiro Nojiri, Shuko Akamatsu, Wado Hattori, Nobutaka |
author_facet | Ueno, Shin-Ichi Saiki, Shinji Fujimaki, Motoki Takeshige-Amano, Haruka Hatano, Taku Oyama, Genko Ishikawa, Kei-Ichi Yamaguchi, Akihiro Nojiri, Shuko Akamatsu, Wado Hattori, Nobutaka |
author_sort | Ueno, Shin-Ichi |
collection | PubMed |
description | Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD. |
format | Online Article Text |
id | pubmed-6356654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63566542019-02-06 Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease Ueno, Shin-Ichi Saiki, Shinji Fujimaki, Motoki Takeshige-Amano, Haruka Hatano, Taku Oyama, Genko Ishikawa, Kei-Ichi Yamaguchi, Akihiro Nojiri, Shuko Akamatsu, Wado Hattori, Nobutaka Cells Article Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD. MDPI 2018-12-29 /pmc/articles/PMC6356654/ /pubmed/30597973 http://dx.doi.org/10.3390/cells8010014 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ueno, Shin-Ichi Saiki, Shinji Fujimaki, Motoki Takeshige-Amano, Haruka Hatano, Taku Oyama, Genko Ishikawa, Kei-Ichi Yamaguchi, Akihiro Nojiri, Shuko Akamatsu, Wado Hattori, Nobutaka Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease |
title | Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease |
title_full | Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease |
title_fullStr | Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease |
title_full_unstemmed | Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease |
title_short | Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease |
title_sort | zonisamide administration improves fatty acid β-oxidation in parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356654/ https://www.ncbi.nlm.nih.gov/pubmed/30597973 http://dx.doi.org/10.3390/cells8010014 |
work_keys_str_mv | AT uenoshinichi zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT saikishinji zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT fujimakimotoki zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT takeshigeamanoharuka zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT hatanotaku zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT oyamagenko zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT ishikawakeiichi zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT yamaguchiakihiro zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT nojirishuko zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT akamatsuwado zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease AT hattorinobutaka zonisamideadministrationimprovesfattyacidboxidationinparkinsonsdisease |